Ki Wook Kim1, Nayoung Kim2,3, Yonghoon Choi1, Won Seok Kim1, Hyuk Yoon1, Cheol Min Shin1, Young Soo Park1, Dong Ho Lee1,4, Young Suk Park5, Sang-Hoon Ahn5, Do Joong Park6, Hyung-Ho Kim5,6, Hye Seung Lee7, Ji-Won Kim1, Jin Won Kim1, Keun-Wook Lee1,4, Won Chang8, Ji Hoon Park8,9, Yoon Jin Lee8, Kyoung Ho Lee8,9, Young Hoon Kim8,9. 1. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. 2. Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea. nakim49@snu.ac.kr. 3. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. nakim49@snu.ac.kr. 4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea. 5. Department of Surgery, Seoul National University Bundang Hospital, Seongnam, South Korea. 6. Department of Surgery, Seoul National University College of Medicine, Seoul, South Korea. 7. Department of Pathology, Seoul National University College of Medicine, Seoul, South Korea. 8. Department of Radiology, Seoul National University Bundang Hospital, Seongnam, South Korea. 9. Department of Radiology, Seoul National University College of Medicine, Seoul, South Korea.
Abstract
BACKGROUND: Inactivation of TP53, a tumor suppressor gene, is associated with the development of several malignancies, including gastric cancer (GC). The present study aimed to evaluate the correlation between the overexpression of p53 and survival in different Lauren-type GCs. METHODS: From May 2003 to December 2019, 3608 GC patients treated endoscopically or surgically at the Seoul National University Bundang Hospital were enrolled for the study. Immunohistochemical staining for p53 was performed on all endoscopic and surgical gastric specimens. Clinicopathologic characteristics with Lauren classification, survival rate, and cancer recurrence were analyzed according to p53 overexpression. RESULTS: Among 3608 GC patients, p53 overexpression was seen in 1334 patients (37%). p53 overexpression was associated with lower depth of invasion (P = 0.026) and Early gastric cancer (P = 0.044) in intestinal-type GC, and with advanced TNM stage (P < 0.001) and Advanced gastric cancer (P < 0.001) in diffuse-type GC. The overall survival (OS) and GC-specific survival (GCSS) were significantly lower in p53 overexpression positive patients. This significance was more pronounced and enhanced in the diffuse-type GC and was absent in the intestinal-type GC. In multivariate analyses, p53 overexpression was associated with poor OS in both subtypes of GC and cancer recurrence in diffuse-type GC. (OS in intestinal-type: adjusted hazard ratio [aHR] = 1.423, P = 0.022; OS in diffuse-type: aHR = 1.401 P = 0.035; cancer recurrence in diffuse-type: aHR = 1.502, P = 0.039). CONCLUSION: p53 overexpression was associated with poor prognosis in GC, especially in diffuse-type. In addition, p53 overexpression was associated with early stage disease in intestinal-type GC and with advanced stage disease in diffuse-type GC.
BACKGROUND: Inactivation of TP53, a tumor suppressor gene, is associated with the development of several malignancies, including gastric cancer (GC). The present study aimed to evaluate the correlation between the overexpression of p53 and survival in different Lauren-type GCs. METHODS: From May 2003 to December 2019, 3608 GC patients treated endoscopically or surgically at the Seoul National University Bundang Hospital were enrolled for the study. Immunohistochemical staining for p53 was performed on all endoscopic and surgical gastric specimens. Clinicopathologic characteristics with Lauren classification, survival rate, and cancer recurrence were analyzed according to p53 overexpression. RESULTS: Among 3608 GC patients, p53 overexpression was seen in 1334 patients (37%). p53 overexpression was associated with lower depth of invasion (P = 0.026) and Early gastric cancer (P = 0.044) in intestinal-type GC, and with advanced TNM stage (P < 0.001) and Advanced gastric cancer (P < 0.001) in diffuse-type GC. The overall survival (OS) and GC-specific survival (GCSS) were significantly lower in p53 overexpression positive patients. This significance was more pronounced and enhanced in the diffuse-type GC and was absent in the intestinal-type GC. In multivariate analyses, p53 overexpression was associated with poor OS in both subtypes of GC and cancer recurrence in diffuse-type GC. (OS in intestinal-type: adjusted hazard ratio [aHR] = 1.423, P = 0.022; OS in diffuse-type: aHR = 1.401 P = 0.035; cancer recurrence in diffuse-type: aHR = 1.502, P = 0.039). CONCLUSION: p53 overexpression was associated with poor prognosis in GC, especially in diffuse-type. In addition, p53 overexpression was associated with early stage disease in intestinal-type GC and with advanced stage disease in diffuse-type GC.
Authors: Takeshi Sano; Daniel G Coit; Hyung Ho Kim; Franco Roviello; Paulo Kassab; Christian Wittekind; Yuko Yamamoto; Yasuo Ohashi Journal: Gastric Cancer Date: 2016-02-20 Impact factor: 7.370
Authors: Simon A Forbes; David Beare; Prasad Gunasekaran; Kenric Leung; Nidhi Bindal; Harry Boutselakis; Minjie Ding; Sally Bamford; Charlotte Cole; Sari Ward; Chai Yin Kok; Mingming Jia; Tisham De; Jon W Teague; Michael R Stratton; Ultan McDermott; Peter J Campbell Journal: Nucleic Acids Res Date: 2014-10-29 Impact factor: 16.971
Authors: Yonghoon Choi; Nayoung Kim; Ki Wook Kim; Hyeong Ho Jo; Jaehyung Park; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee Journal: Ann Geriatr Med Res Date: 2022-03-18
Authors: Yonghoon Choi; Nayoung Kim; Ki Wook Kim; Hyeong Ho Jo; Jaehyung Park; Hyuk Yoon; Cheol Min Shin; Young Soo Park; Dong Ho Lee; Hyeon Jeong Oh; Hye Seung Lee; Young Suk Park; Sang-Hoon Ahn; Yun-Suhk Suh; Do Joong Park; Hyung-Ho Kim; Ji-Won Kim; Jin Won Kim; Keun-Wook Lee; Won Chang; Ji Hoon Park; Yoon Jin Lee; Kyoung Ho Lee; Young Hoon Kim Journal: World J Gastroenterol Date: 2022-03-07 Impact factor: 5.742